On July 7, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company’s continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen for its next stage of development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the segment, Mr. Equels highlights the urgent unmet need facing patients with pancreatic cancer, reviews recent progress across the Company’s DURIPANC Phase 2 clinical program evaluating Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab), and discusses why AIM believes it is entering one of the most catalyst-rich periods in the Company’s history.

Topics discussed include the successful completion of patient enrollment and dosing in the DURIPANC study, encouraging interim clinical observations, continued favorable safety findings, ongoing Phase 3 planning activities, the Company’s strategic collaboration with AstraZeneca and Erasmus Medical Center, expansion of AIM’s intellectual property portfolio and the broader potential of Ampligen to help overcome resistance in immunologically "cold" tumors.

(Press release, AIM ImmunoTech, JUL 7, 2026, View Source [SID1234669086])